- Trials with a EudraCT protocol (147)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
147 result(s) found for: Arginine.
Displaying page 6 of 8.
EudraCT Number: 2015-003551-22 | Sponsor Protocol Number: 55029 | Start Date*: 2016-12-28 | ||||||||||||||||
Sponsor Name:Erasmus MC - Sophia Children's Hospital | ||||||||||||||||||
Full Title: STATIC IV: Efficacy of a loading dose of intravenous salbutamol in patients admitted to a PICU for severe acute asthma | ||||||||||||||||||
Medical condition: Severe acute (viral) wheeze and severe acute asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004413-15 | Sponsor Protocol Number: CSOM230B2209 | Start Date*: 2006-06-07 | |||||||||||
Sponsor Name:Cedars Sinai Medical Center | |||||||||||||
Full Title: Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomas | |||||||||||||
Medical condition: non-functioning pitiutary adenomes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005332-25 | Sponsor Protocol Number: P903-06 | Start Date*: 2007-03-16 | |||||||||||
Sponsor Name:Cerexa, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and ... | |||||||||||||
Medical condition: Complicated Skin and Skin Structure Infections (cSSSI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004231-38 | Sponsor Protocol Number: 08-BO-VIBH | Start Date*: 2009-01-26 | |||||||||||
Sponsor Name:Department of Medicine I, University Hospital St.Josef-Hospital, Ruhr University Bochum | |||||||||||||
Full Title: Effects of vildagliptin (Galvus®) on beta-cell function and turnover in humans | |||||||||||||
Medical condition: Diabetes mellitus, beta-cell function before and after pancreatic surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003460-38 | Sponsor Protocol Number: HPN-100-009 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:Horizon Therapeutics, LLC | |||||||||||||
Full Title: An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs) | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005889-40 | Sponsor Protocol Number: ABR-15108 | Start Date*: 2007-08-14 | |||||||||||
Sponsor Name:Academic Medical Centre | |||||||||||||
Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease | |||||||||||||
Medical condition: Patients homozygous for sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003865-23 | Sponsor Protocol Number: HPN-100-004 | Start Date*: 2008-09-08 | |||||||||||
Sponsor Name:Hyperion Therapeutics Limited | |||||||||||||
Full Title: A Phase 2, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 (glyceryl tri-[4-phenylbutyrate]) Compared to Sodium Phenylbutyrate in Adult and Pediatric Subjects with Urea... | |||||||||||||
Medical condition: Urea Cycle Disorder (urea cycle enzyme or transporter deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002877-71 | Sponsor Protocol Number: 261409 | Start Date*: 2018-02-28 |
Sponsor Name:European Commission FP7 Health 2010 | ||
Full Title: cGMP Enhancing Therapeutic Strategy for HFpEF: The cGETS Study An interventional, single blind, multicentre study. | ||
Medical condition: HFpEF patients over 18 years old and concomitant arterial hypertension, overweight or obesity and pulmonary hypertension. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019424-31 | Sponsor Protocol Number: REP0110 | Start Date*: 2010-08-31 | |||||||||||
Sponsor Name:Dompé s.p.a. | |||||||||||||
Full Title: A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following islet transplantation in patients with type 1 diabetes mellitus | |||||||||||||
Medical condition: intrahepatic islet transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005401-20 | Sponsor Protocol Number: CSLCT-BIO-03-97 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:CSL Limited | |||||||||||||
Full Title: An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD) | |||||||||||||
Medical condition: Von Willebrand's disease (VWD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001382-10 | Sponsor Protocol Number: CS/2015/4775 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | |||||||||||||
Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service | |||||||||||||
Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003776-40 | Sponsor Protocol Number: CL-N-CSM-AV-III/05/12 | Start Date*: 2013-11-08 |
Sponsor Name:Dr. Franz Köhler Chemie GmbH | ||
Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N versus Custodiol | ||
Medical condition: Patients with aortic valve disease and has to undergo aortic valve surgery +/- bypass surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005503-13 | Sponsor Protocol Number: 1.0_Custodiol | Start Date*: 2015-02-16 | |||||||||||
Sponsor Name:Essen University Hospital, University of Essen, Klinik für Allgemein-, Viszeral- und Transplantationschirugie | |||||||||||||
Full Title: A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation | |||||||||||||
Medical condition: kidney preservation by Custodiol-N or Custodiol solution before living related kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000075-27 | Sponsor Protocol Number: HPN-100-021 | Start Date*: 2016-03-07 | |||||||||||
Sponsor Name:Horizon Therapeutics, LLC | |||||||||||||
Full Title: A Randomised, Controlled, Open-Label Parallel Arm Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA)... | |||||||||||||
Medical condition: Urea Cycle Disorders (UCDs) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004317-90 | Sponsor Protocol Number: NL51058.091.14 | Start Date*: 2015-02-25 | |||||||||||||||||||||
Sponsor Name:Radboud University Medical Center Nijmegen | |||||||||||||||||||||||
Full Title: Visualizing beta cells in patients with remission of T2DM after bariatric surgery | |||||||||||||||||||||||
Medical condition: Patients with Type 2 Diabetes, with or without remission after bariatric surgery | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002198-20 | Sponsor Protocol Number: CLNKLPTXIII07AT17 | Start Date*: 2018-11-28 |
Sponsor Name:Dr. Franz Köhler Chemie GmbH | ||
Full Title: A Prospective, randomized, single blind, multicentre Phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in organ transplantation (kidney, liver and pan... | ||
Medical condition: patients who will undergo kidney, liver or kidney-pancreatic transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001477-33 | Sponsor Protocol Number: 071102 | Start Date*: 2016-12-01 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleed... | |||||||||||||
Medical condition: Hereditary severe von Willebrand Disease in children | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Completed) ES (Trial now transitioned) FR (Trial now transitioned) DE (Completed) NL (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000929-42 | Sponsor Protocol Number: TCH-306 | Start Date*: 2021-06-09 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ... | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000196-24 | Sponsor Protocol Number: 402-C-1504 | Start Date*: 2016-07-04 |
Sponsor Name:Reata Pharmaceuticals, Inc. | ||
Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION | ||
Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-000830-37 | Sponsor Protocol Number: CP-4-005 | Start Date*: 2013-07-03 | |||||||||||
Sponsor Name:OPKO Biologics Ltd. | |||||||||||||
Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult or childhood onset growth hormone deficiency (GHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
